A Collaborative Search for Efficient Methods of Ensuring Unchanged Product Quality and Performance During Scale-Up of Immediate-Release Solid Oral Dosage Forms

Pharmaceutical Process Scale-Up

Volumn , Issue , 2001, Pages 325-352

  Hussain, Ajaz S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85147054804     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780824741969-18     Document Type: Chapter

References (50)

1. Guideline on General Principles of Process Validation, May 1987. Center for Drug Evaluation and Research, Food and Drug Administration. http://www.fda.gov/cder/ guidance/pv.htm.
2. ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Issued 11/1997, Posted 11/25/1997.http://www.fda.gov/cder/guidance/index.htm.
3. Skelly, J. P., Van Buskrik, G. A., Savello, D. R., et al. Workshop report: scale-up of immediate release oral solid dosage forms. Pharm. Res. 10:313–316, 1993.
4. Augsburger, L. L., Shangraw, R., Lesko, L. J., and Williams, R. W. An approach toward establishing a scientific foundation for interpreting regulations and workshop reports on scale-up and post approval changes. Pharm. Res. 11(10): S-143, 1994.
5. SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. November 1995. Center for Drug Evaluation and Research, Food and Drug Administration.http://www.fda.gov/cder/guidance/index.htm.
6. The Product Quality Research Institute, Inc. www.pqri.org
7. Webster’s Third New International Dictionary of the English Language. G. & C. Merriam Company, Springfield, MA, 1976.
8. Ullah, I., Wiley, G. J., and Agharkar, S. N. Analysis and simulation of capsule dissolution problem encountered during product scale-up. Drug. Dev. Ind. Pharm. 18(8): 895–910, 1992.
9. Heda, P. K. A comparative study of the formulation requirements of dosator and dosing disc encapsulators, simulation of plug formation, and creation of rules for an expert system for formulation design. Ph.D. Dissertation, University of Maryland, School of Pharmacy, 1998.
10. Guidance for Industry. Changes to an Approved NDA or ANDA. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), November 1999. http://www.fda.gov/cder/guidance/2 766fnl.htm.
11. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Optional Format: PDF. Issued 8/2000, Posted 8/31/2000. http://www.fda.gov/cder/guidance/ index.htm.
12. SUPAC-IR/MR: Immediate Release and Modified Release Solid Oral Dosage Forms Manufacturing Equipment Addendum. Issued 1/1999, Posted 2/25/1999. http:// www.fda.gov/cder/guidance/index.htm.
13. Carstensen, J. T. Preformulation. In: J. T. Carstensen and C. T. Rhodes, eds. Drug Stability: Principles and Practices. Third Eds Marcel Dekker, New York, 2000, Chap 9, p 237.
14. Samyn, J. C., and Jung, W. Y. In vitro dissolution from several experimental capsule formulations. J. Pharm. Sci. 59:169–175, 1970.
15. Rowley, G., and Newton, J. M. Limitations of liquid penetration in predicting the release of drugs from hard gelatin capsules. J. Pharm. Pharmacol. 22:966–967, 1970.
16. Newton, J. M., Rowley, G., and Tornblom, J. F. Effect of additives on the release of drug from hard gelatin capsules. J. Pharm. Pharmacol. 23:452–453, 1971.
17. Khalil, S. A., and Ali, M. M. Some formulation factors affecting disintegration and dissolution of chloramphenicol capsules. Acta. Pharm. Suec. 9:563–572, 1972.
18. Caldwell, H. C., and Westlake, W. J. Magnesium lauryl sulfate–soluble lubricant. J. Pharm. Sci. 61:984–985, 1972.
19. Caldwell, H. C. Dissolution of lithium and magnesium from lithium carbonate capsules containing magnesium stearate. J. Pharm. Sci. 63:770–773, 1974.
20. Murthy, K. S., and Samyn, J. C. Effect of shear mixing on in vitro drug release of capsule formulations containing lubricants. J. Pharm. Sci. 66:1215–1219, 1977.
21. Newton, J. M., and Razzo, F. N. Influence of additives on the presentation of a drug in hard gelatin capsules. J. Pharm. Pharmacol. 29:294–297, 1977.
22. Shah, A. C., and Mlodozeniec, A. R. Mechanism of surface lubrication: influence of duration of lubricant–excipient mixing on processing characteristics of powders and properties of compressed tablets. J. Pharm. Sci. 66:1377–1382, 1977.
23. Stewart, A. G., Grant, D. J. W., and Newton, J. M. Release of a model low dose drug (riboflavin) from hard gelatin capsule formulations. J. Pharm. Pharmacol. 31:1–6, 1979.
24. Ahmed, M., and Enever, R. P. Influence of magnesium stearate on physical properties and biological availability of sulfadiazine tablet formulations. Pharm. Acta. Helv. 53:358–364, 1978.
25. Mehta, A. M., and Augsburger, L. L. Preliminary study of the effect of slug hardness on drug dissolution from hard gelatin capsules filled on an automatic capsule filling machine. Int. J. Pharm. 7:327–334, 1981.
26. Johansson, M. E., and Nicklasson, M. Investigation of the film formation of magnesium stearate by applying a flow through dissolution technique. J. Pharm. Pharmacol. 38:51–54, 1986.
27. Chowhan, Z. T., and Chi, L. H. Drug-excipient interactions resulting from powder mixing. Part 3. Solid-state properties and their effect on drug dissolution. J. Pharm. Sci. 75:534–541, 1986.
28. Chowhan, Z. T., and Chi, L. H. Drug–excipient interactions resulting from powder mixing. Part 4. Role of lubricants and their effect on in vitro dissolution. J. Pharm. Sci. 75:542–545, 1986.
29. Wang, L. H., and Chowhan, Z. T. Drug–excipient interactions resulting from powder mixing. Part 5. Role of sodium lauryl sulfate. Int. J. Pharm. 60:61–78, 1990.
30. Desai, D. S., Rubitski, B. A., Varia, S. A., and Newman, A. W. Physical interactions of magnesium stearate with starch-derived disintegrants and their effects on capsule and tablet dissolution. Int. J. Pharm. 91:217–226, 1993.
31. Ong, J. T., Chowhan, Z. T., and Samuels, G. J. Drug–excipient interactions resulting from powder mixing. Part 6. Role of various surfactants. Int. J. Pharm. 96:231–242, 1993.
32. Barra, J., and Somma, R. Influence of the physicochemical variability of magnesium stearate on its lubricant properties: possible solutions. Drug. Dev. Ind. Pharm. 22:1105–1120, 1996.
33. Harwood, R. J., and Molnar, S. A. Using design of experiments (DOE) techniques to avoid process problems. Pharm. Dev. Tech. 3:577–578, 1998.
34. Shangraw, R. F., and Demarest, D. Survey of current industrial practice in the formulation and manufacture of tablets and capsules. Pharm. Tech. 17(1):32–44, 1993.
35. USP 24-NF 19. United States Pharmacopoeia Convention, Inc. Rockville, MD, 2000.
36. Piscitelli, D. A., Bigora, S., Propst, C., Goskonda, S., Young, D., et al. Impact of formulation process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Pharm. Dev. Technol. 3:443–452, 1998.
37. Hussain, A. S., Lesko, L. J., Lo, H, Y., Shah, V. P., Volpe, D., and Williams, R. L. The Biopharmaceutics Classification System: Highlights of the FDA’s Draft Guidance. Dissolution Technol. 6:5–9, 1999.
38. Amidon, G. L., Lennernas, H., Shah, V. P., et al. A theoretical basis for a biopharmaceutics drug classification system: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413–420, 1995.
39. Lindahl, A., Ungell, A. L., Knutson, L., and Lennernas, H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm. Res. 14: 497–502, 1997.
40. Kaus, L. C., Gillespie, W. R., Hussain, A. S., and Amidon, G. A. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm. Res. 16:272–280, 1999.
41. Billany, M. R., and Richards, J. H. Batch variation of magnesium stearate and its effect on the dissolution rate of salicylic acid from solid dosage forms. Drug. Dev. Ind. Pharm. 8:497–511, 1982.
42. Meyer, M. C., Straughn, A. B., Mhatre, R. M., et al. The effect of gelatin cross-linking on the bioequivalence of hard and soft gelatin acetaminophen capsules. Pharm. Res. 17:962–966, 2000.
43. Moore, J. W., and Flanner, H. H. Mathematical comparison of dissolution profiles. Pharm. Technol. 20:54–75, 1996.
44. Draft Guidance for Industry. Stability Testing of Drug Substances and Drug Products, 1998. http://www.fda.gov/cder/guidance/1707dft.pdf.
45. Carstensen, J. T. Physical Testing. In: J. T. Carstensen and C. T. Rhodes, eds. Drug Stability: Principles and Practices. Third Edition, Marcel Dekker, New York, 2000, Chap 10, p 261.
46. Drug Recalls Declined for 1998. The Gold Sheets. Vol. 33. February 1999.
47. Murthy, K. S., and Ghebere-Sellassie, I. Current perspectives on the dissolution stability of solid dosage forms. J. Pharm. Sci. 82:113–26, 1993.
48. Hussain, A. S. Biopharmaceutics Classifications System. Advisory Committee for Pharmaceutical Science meeting, 11 December 1997. Food and Drug Administration. http://www/fda.gov/ohrms/dockets/ac/97/transcpts/3350.pdf.
49. Pharmaceutical Industry Cost Savings Through Use of the Scale-up and Post-Approval Change Guidance for Immediate Release Solid Oral Dosage Forms (SUPACIR). Office of Planning and Evaluation, Food and Drug Administration, 1998. http://www.fda.gov/ope/supac5.pdf.
50. Chiu, Y. Y. Risk-Based Chemistry Review. Advisory Committee for Pharmaceutical Science. Center for Drug Evaluation and Research, Food and Drug Administration. November 2000. (The Gold Sheet also reported on this discussion. Risk-Based CMC Review Plan Unveiled by FDA’s Drug Center. November 2000.)